Evaluating the Safety and Efficacy of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women

HIV Infections Clinical Trial

Official title:

A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03164564
• Other study ID #: HPTN 084
• Secondary ID: 38070
• Status: Active, not recruiting
• Phase: Phase 3
• Start date: November 7, 2017
• Est. completion date: November 30, 2024

Study information

• Verified date: March 2023
• Source: National Institute of Allergy and Infectious Diseases (NIAID)
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will evaluate the safety and efficacy of the long-acting injectable agent cabotegravir (CAB LA) compared to daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for pre-exposure prophylaxis (PrEP) in HIV-uninfected women.

Description:

The purpose of this study is to evaluate the safety and efficacy of the long-acting injectable integrase inhibitor cabotegravir (CAB LA) compared to daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for pre-exposure prophylaxis (PrEP) in a population of sexually active HIV-uninfected women at risk for HIV. This study will take place in three steps. Participants will be randomly assigned to one of two arms: Arm A: Step 1: Participants will receive daily oral CAB and TDF/FTC placebo for 5 weeks. Step 2: Participants will receive injections of CAB LA at two time points 4 weeks apart and every 8 weeks thereafter and daily TDF/FTC placebo beginning at Week 5. Arm B: Step 1: Participants will receive daily TDF/FTC and oral CAB placebo for 5 weeks. Step 2: Participants will receive daily TDF/FTC and intramuscular (IM) placebo injections at two time points 4 weeks apart and every 8 weeks thereafter beginning at Week 5. Step 2 will continue until the last enrolled participant reaches approximately 76 weeks on Step 2 (Week 81 for the last enrolled participant). In Step 3, all participants (Arms A and B) will receive daily TDF/FTC for up to 48 weeks, starting no later than 8 weeks after the last injection. At the end of Step 3, all participants will then transition to locally available HIV prevention services, including services for PrEP, if available. Study visits will occur at Day 0 and at Weeks 2 and 4 during Step 1. During Step 2, participants will attend up to 24 visits, depending on when they enroll in the study. Study visits will occur every 12 weeks during Step 3. Study visits may include physical examinations; blood, urine, and vaginal swab collection; risk reduction, adherence counseling, and contraception counseling. HPTN 084-01 is a sub-study of HPTN 084. The purpose of this study is to examine the safety, tolerability, and acceptability of CAB LA for the prevention of HIV among adolescent females. Participants will receive oral CAB for 5 weeks, followed by 34 weeks on CAB LA, then quarterly visits for 48 weeks after final injection. All participants who have received at least one injection will be followed for 48 weeks after their last injection. Total study duration per participant will be approximately 21 months.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 3224
• Est. completion date: November 30, 2024
• Est. primary completion date: November 5, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• Born female
• 18-45 years at the time of screening
• Willing and able to provide informed consent
• Willing and able to undergo all required study procedures
• Non-reactive HIV test results at Screening and Enrollment. Note: HIV-uninfected, based on HIV test results obtained at Screening and just prior to randomization at the Enrollment visit. All HIV test results from the Screening visit must be obtained and must all be negative/non-reactive. This includes testing for acute HIV infection, which must be performed within 14 days of Enrollment. In addition, at least one HIV test result using blood drawn at the Enrollment visit must be obtained prior to randomization into the study and must be negative/non-reactive. Individuals who have one or more reactive or positive HIV test result(s) will not be enrolled, even if subsequent confirmatory testing indicates that they are not HIV-infected (see SSP Manual). Those with any enrollment HIV test result positive will proceed through the HIV algorithm per the SSP but will not be able to receive study product regardless of subsequent test results.
• Sexually active (i.e., vaginal intercourse on a minimum of two separate days in the 30 days prior to Screening)
• Score of greater than or equal to 5 using a modified VOICE risk score
• No plans to re-locate or travel away from the site for greater than or equal to 8 consecutive weeks during study participation
• Creatinine clearance of greater than or equal to 60 mL/min (using Cockcroft-Gault equation) (use sex at birth for calculation)
• Although not protocol exclusionary, sites should carefully consider the advisability of enrolling participants with calculated creatinine clearance between 60-70 mL/min, as limited changes in creatinine clearance during study conduct will lead to protocol-mandated product holds and may alter the risk-benefit considerations of study participation
• Hepatitis B virus (HBV) surface antigen (HBsAg) negative and accepts vaccination
• Alanine aminotransferase (ALT) less than 2 x upper limit of normal (ULN) and total bilirubin (Tbili) less than or equal to 2.5 x ULN
• HCV antibody negative
• If of reproductive potential (defined as pre-menopausal women who have not had a sterilization procedure per self-report, such as hysterectomy, bilateral oophorectomy, tubal ligation or salpingectomy), must have a negative beta human chorionic gonadotropin (ßHCG) pregnancy test (sensitivity of less than or equal to 25 mIU/mL) performed (and results known) on the same day as and before initiating the protocol-specified study product(s) at Enrollment.
• Have documented evidence of surgical sterilization, OR documented evidence of no uterus (e.g., hysterectomy), OR must agree to use a reliable form of long acting contraception, during the trial and for 52 weeks after stopping the long acting

injectable, or 30 days after stopping oral study product, from the list below:

• Intrauterine device (IUD) or intrauterine system (IUS) that meets less than 1% failure rate as stated in the product label
• Hormone-based contraceptive that meets less than 1% failure rate when used consistently and correctly as stated in the product label (implants or injectables only; this excludes combined oral contraception)
• No medical condition that, in the opinion of the study investigator, would interfere with the conduct of the study (e.g., provided by self-report, or found upon medical history and examination or in available medical records)
• No alcohol or substance use that, in the opinion of the study investigator, would interfere with the conduct of the study (e.g., provided by self-report, or found upon medical history and examination or in available medical records)

Exclusion Criteria:

• One or more reactive HIV test results at Screening or Enrollment, even if HIV infection is not confirmed
• Pregnant or currently breastfeeding, or intends to become pregnant and/or breastfeed during the study
• Co-enrollment in any other HIV interventional research study (provided by self-report or other available documentation), with one exception: IMPAACT 2026 (co-enrollment in IMPAACT 2026 is permitted for participants who become pregnant)
• Current or past enrollment in an HIV vaccine or broadly neutralizing antibody trial
• Current or chronic history of liver disease (e.g., non-alcoholic or alcoholic steatohepatitis) or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome, asymptomatic gallstones, or cholecystectomy)
• History of seizure disorder, per self-report
• Clinically significant cardiovascular disease, as defined by history/evidence of symptomatic arrhythmia, angina/ischemia, coronary artery bypass grafting (CABG) surgery or percutaneous transluminal coronary angioplasty (PTCA) or any clinically significant cardiac disease
• Inflammatory skin conditions that compromise the safety of IM injections, per the discretion of the Investigator of Record (IoR). Mild skin conditions may not be exclusionary at the discretion of the IoR or designee
• Has a tattoo or other dermatological condition overlying the buttock region which in the opinion of the IoR or designee may interfere with interpretation of injection site reactions (ISRs)
• Coagulopathy (primary or iatrogenic) which would contraindicate IM injection
• Active or planned use of prohibited medications as described in the Investigator Brochure (IB) or listed in the Study Specific Procedures Manual (SSP) (provided by self-report, or obtained from medical history or medical records)
• Known or suspected allergy to study product components (active or placebo), including egg or soy products (egg and soy products are contained in Intralipid)
• If potentially able to conceive, unwilling to adhere to long acting contraception (IUD/IUS, injection, or implant) with a less than 1% failure rate when used consistently and correctly as stated in the product package insert/ manufacturer's guidelines

Related Conditions & MeSH terms

• HIV Infections

Intervention

Drug:
• Oral CAB
CAB 30 mg tablet
• Oral TDF/FTC
TDF/FTC 300 mg/200 mg fixed dose combination tablet
• Placebo for oral CAB
Placebo tablets
• Placebo for oral TDF/FTC
Placebo tablets
• CAB LA
600 mg administered as one 3 mL (600 mg) intramuscular injection in the gluteal muscle
• Placebo for CAB LA
Administered as one 3 mL intramuscular injection in the gluteal muscle

Locations

Country	Name	City	State
Botswana	Gaborone CRS	Gaborone	South-East District
Kenya	Kisumu Crs	Kisumu	Nyanza
Malawi	Blantyre CRS	Blantyre
Malawi	Malawi CRS	Lilongwe	Central
South Africa	Desmond Tutu TB Centre - Stellenbosch University (DTTC-SU) CRS	Cape Town	Western Cape Province
South Africa	Emavundleni CRS	Cape Town	Western Cape
South Africa	Botha's Hill CRS	Durban	Kwa Zulu Natal
South Africa	Isipingo CRS	Isipingo	Kwa Zulu Natal
South Africa	Soweto HPTN CRS	Johannesburg	Gauteng
South Africa	Ward 21 CRS	Johannesburg	Gauteng
South Africa	Verulam CRS	Verulam	Kwa Zulu Natal
Swaziland	Eswatini Prevention Center CRS	Mbabane	Eswatini
Uganda	UVRI-IAVI HIV Vaccine Program LTD. CRS	Entebbe
Uganda	Baylor-Uganda CRS	Kampala
Uganda	MU-JHU Research Collaboration (MUJHU CARE LTD) CRS	Kampala
Zimbabwe	Seke South CRS	Chitungwiza
Zimbabwe	St Mary's CRS	Chitungwiza
Zimbabwe	Zengeza CRS	Chitungwiza	Mashonaland East
Zimbabwe	Milton Park CRS	Harare
Zimbabwe	Spilhaus CRS	Harare

Sponsors (1)

Lead Sponsor	Collaborator
National Institute of Allergy and Infectious Diseases (NIAID)

Countries where clinical trial is conducted

Botswana,  Kenya,  Malawi,  South Africa,  Swaziland,  Uganda,  Zimbabwe, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Pariicipants With Documented Incident HIV Infections	The number of participants with an incident HIV infection that is confirmed by the HPTN Laboratory Center and Endpoint Adjudication Committee.	HIV tests at enrollment, weeks 2, 4, and 5, then every 4 weeks through week 25, then every 8 weeks. Analyzed through week 185 or the date of DSMB decision to unblind all participants, whichever is earliest.
Primary	Number of Participants Who Experienced Grade 2 or Higher Clinical and Laboratory Adverse Events (AEs) in Steps 1 and 2	AEs will be summarized using MedDRA System Organ Class and preferred terms.	Treatment emergent AE measured with onset date through participant's last study visit, or the date of DSMB decision to unblind all participants, whichever is earliest. Assessed at each visit (injections visits q 8 weeks and safety visits q 8 weeks)